Cefditoren-d3 (sodium)

Cefditoren-d3 (sodium) (ME 1206-d3) is deuterium labeled Cefditoren (sodium) . Cefditoren sodium (ME 1206) is a broad-spectrum, third-generation, oral cephalosporin antibacterial with enhanced stability against many common β lactamases. Cefditoren sodium has activity against Gram-negative organisms and Gram-positive organisms. Cefditoren sodium can be used in the research of infection diseases such as acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), streptococcal pharyngitis/tonsillitis, or uncomplicated skin and skin structure infections[1][2].

Product Specifications

Product Name Alternative

ME 1206-d3

UNSPSC

12352005

Target

Bacterial; Beta-lactamase; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology

Smiles

O=C(C1=C(/C=C\C2=C(N=CS2)C)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC([2H])([2H])[2H])=O)([H])N1C3=O)O[Na]

Molecular Formula

C19H14D3N6NaO5S3

Molecular Weight

531.58

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wellington K, et al. Cefditoren pivoxil: a review of its use in the treatment of bacterial infections. Drugs. 2004;64 (22) :2597-618.|[3]Cafini F, et al. Enhanced in vivo activity of cefditoren in pre-immunized mice against penicillin-resistant S. pneumoniae (serotypes 6B, 19F and 23F) in a sepsis model. PLoS One. 2010 Aug 10;5 (8) :e12041.